Sonnet BioTherapeutics has announced a merger with Rorschach I LLC, resulting in the formation of Hyperliquid Strategies, which will launch a HYPE treasury strategy. The deal, valued at $888 million, will include the issuance of 12.6 million HYPE tokens and $305 million in cash, with participation from several strategic investors.